Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gian Life Care's board met on August 14, 2025 and approved audited standalone and consolidated financial results for Q4/FY ended March 31, 2025, along with unaudited Q1FY26 results ended June 30, 2025. The auditor (MSNT & Associates LLP) issued a QUALIFIED opinion on both sets of results, flagging two concerns: (1) IPO proceeds of ₹311.52 lakhs not fully utilised on the proposed objects (a recurring qualification for the 6th year), and (2) the company holding ₹693.86 lakhs in cash (standalone) despite ₹421.99 lakhs in unpaid statutory dues (income tax, PF, ESI, TDS), with the auditor unable to physically verify the cash balance. Standalone FY25 revenue collapsed to ₹663.10 lakhs from ₹1,311.98 lakhs in FY24 (-49%), net profit fell to ₹15.51 lakhs from ₹429.57 lakhs (-96%), and EPS dropped to ₹0.14 from ₹4.16. On a consolidated basis, the company slipped into a loss of ₹4.47 lakhs (vs profit of ₹415.22 lakhs) with negative EPS of ₹0.04, while Q4FY25 standalone showed a loss of ₹47.67 lakhs.
Shareholders should treat this as a red flag — a qualified audit opinion combined with a sharp revenue and profit collapse, unpaid statutory dues piling up against a large unverified cash balance, and persistent misuse of IPO proceeds signals weak governance and deteriorating fundamentals. The stock is likely to face negative sentiment, and investors should monitor whether management clears the tax dues and deploys cash toward stated objectives.